Actualités Meet Kevin Pricing Power ETF - PP | Actions American Stock Exchange

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

The Meet Kevin Pricing Power ETF (PP) to Close

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tidal Financial Group and Plato’s Philosophy LLC announce the...

- Statement of Beneficial Ownership (SC 13D)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Pipex...

Pipex Pharmaceuticals, Inc. - Amended Annual Report (Small Business Issuers) (10KSB/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-KSB/A AMENDMENT No. 1 ANNUAL REPORT...

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ý...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13...

Pipex Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (SC 13D/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION STATEMENT PURSUANT TO RULES 13D-1 AND...

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE...

Pipex Pharmaceuticals, Inc. - Proxy Statement (definitive) (DEF 14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY...

Pipex Pharmaceuticals, Inc. - Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY...

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Meet Kevin Pricing Power ETF (PP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Meet Kevin Pricing Power ETF (PP) Actualités

The Meet Kevin Pricing Power ETF (PP) to Close

- Statement of Beneficial Ownership (SC 13D)

Pipex Pharmaceuticals, Inc. - Amended Annual Report (Small Business Issuers) (10KSB/A)

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (SC 13D/A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Proxy Statement (definitive) (DEF 14A)

Pipex Pharmaceuticals, Inc. - Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Meet Kevin Pricing Power ETF (PP)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Meet Kevin Pricing Power ETF (PP) Actualités

The Meet Kevin Pricing Power ETF (PP) to Close

- Statement of Beneficial Ownership (SC 13D)

Pipex Pharmaceuticals, Inc. - Amended Annual Report (Small Business Issuers) (10KSB/A)

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (SC 13D/A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Proxy Statement (definitive) (DEF 14A)

Pipex Pharmaceuticals, Inc. - Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités